Ferring announces new Ambition, Enterprise Model and Executive Committee composition to accelerate growth and innovation
Ferring is pleased to unveil a new Ambition and Enterprise Model designed to sharpen our strategic focus and drive sustainable growth. To enable the new model, we also announce key changes to our Executive Committee.
Saint-Prex, Switzerland – 10 September 2025 – Ferring Pharmaceuticals today announced leadership changes and a new strategic direction to support its renewed Ambition.
Introducing Ferring’s new Ambition and Enterprise Model
Our Ambition: Family is at the heart of Ferring. We strive to unlock opportunities to deliver transformative solutions to patients, bringing hope and joy to families across the world.
To fulfill our Ambition, Ferring is launching a new Enterprise Model that organises our business into two distinct value-generating areas:
- Core Business: Strengthening our current product portfolio to serve more patients today and create a stable foundation for future investments.
- Portfolio: Driving future growth through external innovation and strong execution of clinical trials, with a focus on mid- to late-stage development opportunities that align with our strengths as a mid-sized, privately owned company.
The Executive Committee
- Operations – Cyril Grandchamp-Desraux
- In the new structure, Operations will include our Medical and Commercial organisations enabling seamless collaboration in the interest of our patients while driving strong local empowerment to grow the business.
- Clinical and Pharmaceutical Development – Tamara Vukmirovic
- A Ferring veteran since 2005, Tamara brings deep expertise and leadership to accelerate development projects and clinical trials.
- Technical Operations – Armin Metzger
- In the new structure, Technical Operations will also encompass Global Regulatory Affairs, reinforcing our commitment to excellence and compliance.
- People & Communications – Christelle Beneteau
- Finance, IT, Procurement, ESG – Dominic Moorhead
Leadership transitions and governance enhancements
- Pierre-Yves Berclaz, Chief Medical and Science Officer, will take early retirement. We thank him for his dedicated service and leadership.
- A new Science, Medicine and Development Council will be formed and chaired by board member Dr. Michael Rosenblatt. It will provide advice and oversight for clinical development, medical affairs, regulatory, and pharmacovigilance under the authority of the Board of Directors. This will replace the current R&D and Production Committee of the Ferring Holding SA Board of Directors.
Jean-Frédéric Paulsen, Chairman of the Board says: “This is an exciting moment for Ferring. With a renewed leadership team and a sharper strategic focus, we are positioning ourselves to deliver even greater value to patients and partners. Our new Enterprise Model reflects our commitment to both operational excellence and bold innovation. It’s about building on our strengths while preparing for the future — and I couldn’t be more confident in the team leading us forward.”
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in gastroenterology and urology and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries.